Cingulate to Present at Aegis Virtual Conference
February 15 2022 - 6:45AM
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical
company utilizing its proprietary Precision Timed Release™ (PTR™)
drug delivery platform technology to build and advance a pipeline
of next-generation pharmaceutical products, today announced that
Shane J. Schaffer, Chairman and Chief Executive Officer, will
present a company overview at the Aegis Capital Corp. Virtual
Conference on February 24, 2022, at 10:30 a.m. ET.
Cingulate’s presentation will be available by request to Aegis
for the duration of the conference, from February 23 through
February 25.
To access the event, you may download and import the following
iCalendar (.ics) files to your calendar system: Aegis Virtual
Conference Calendar. A webcast of the presentation can also be
accessed on the Investors section of Cingulate’s website at
cingulate.com/investors. A replay of the webcast will be available
for 30 days following the event.
About
Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage
biopharmaceutical company utilizing its proprietary Precision Timed
Release™ (PTR™) drug delivery platform technology to build and
advance a pipeline of next-generation pharmaceutical products,
designed to improve the lives of patients suffering from frequently
diagnosed conditions characterized by burdensome daily dosing
regimens and suboptimal treatment outcomes. With an initial focus
on the treatment of Attention Deficit/Hyperactivity Disorder
(ADHD), Cingulate is identifying and evaluating additional
therapeutic areas where PTR technology may be employed to develop
future product candidates, including to treat anxiety
disorders.
Cingulate is headquartered in Kansas City. For
more information visit Cingulate.com
Investor Relations Thomas Dalton: Head of
Investor & Public Relations, Cingulate,
Inc.TDalton@cingulate.com913-942-2301
Andy Brimmer / Amy Feng: Joele Frank, Wilkinson Brimmer
Katcherabrimmer@joelefrank.com afeng@joelefrank.com
212-355-4449
Media RelationsMelyssa Weible: Elixir Health
Public Relationsmweible@elixirhealthpr.com201-723-5805
CING-US-101-0223
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024